A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Administration of HM12470 in Subjects With Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Hanmi Pharmaceutical
- 07 Apr 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 07 Apr 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 03 Jun 2015 Data from this trial will be presented at the American Diabetes Association's 75th Scientific Sessions, according to a Hanmi Pharmaceuticals media release.